Long-term outcome of Epstein–Barr virus DNAemia and PTLD with the use of preemptive rituximab following allogeneic HSCT

References

• Landgren O, Gilbert ES, Rizzo JD, et al. Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation [Evaluation Studies Multicenter Study Research Support, N.I.H., Extramural Research Support, N.I.H., Intramural Research Support, Non-U.S. Govt]. Blood. 2009;113:4992–5001.
   PubMed Web of Science ®Google Scholar
• Sundin M, Le Blanc K, Ringden O, et al. The role of HLA mismatch, splenectomy and recipient Epstein–Barr virus seronegativity as risk factors in post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation. Haematologica. 2006;91:1059–1067.
   PubMed Web of Science ®Google Scholar
• Baker KS, DeFor TE, Burns LJ, et al. New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors [Research Support, Non-U.S. Govt Research Support, U.S. Govt, P.H.S.]. JCO. 2003;21:1352–1358.
   PubMed Web of Science ®Google Scholar
• Cohen JM, Cooper N, Chakrabarti S, et al. EBV-related disease following haematopoietic stem cell transplantation with reduced intensity conditioning [Review]. Leuk Lymphoma. 2007;48:256–269.
   PubMed Web of Science ®Google Scholar
• Brunstein CG, Weisdorf DJ, DeFor T, et al. Marked increased risk of Epstein–Barr virus-related complications with the addition of antithymocyte globulin to a nonmyeloablative conditioning prior to unrelated umbilical cord blood transplantation. Blood. 2006;108:2874–2880.
   PubMed Web of Science ®Google Scholar
• Xu LP, Zhang CL, Mo XD, et al. Epstein–Barr virus-related post-transplantation lymphoproliferative disorder after unmanipulated human leukocyte antigen haploidentical hematopoietic stem cell transplantation: incidence, risk factors, treatment, and clinical outcomes. Biol Blood Marrow Transplant. 2015;21:2185–2191.
   PubMed Web of Science ®Google Scholar
• Peric Z, Cahu X, Chevallier P, et al. Features of EBV reactivation after reduced intensity conditioning unrelated umbilical cord blood transplantation. Bone Marrow Transplant. 2012;47:251–257.
   PubMed Web of Science ®Google Scholar
• Kamani NR, Kumar S, Hassebroek A, et al. Malignancies after hematopoietic cell transplantation for primary immune deficiencies: a report from the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Transplant. 2011;17:1783–1789.
   PubMed Web of Science ®Google Scholar
• Styczynski J, van der Velden W, Fox CP, et al. Management of Epstein–Barr virus infections and post-transplant lymphoproliferative disorders in patients after allogeneic hematopoietic stem cell transplantation: sixth European Conference on Infections in Leukemia (ECIL-6) guidelines. Haematologica. 2016;101:803–811.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Einsele H, Gil L, et al. Outcome of treatment of Epstein–Barr virus-related post-transplant lymphoproliferative disorder in hematopoietic stem cell recipients: a comprehensive review of reported cases. Transpl Infect Dis. 2009;11:383–392.
   PubMed Web of Science ®Google Scholar
• Avivi I, Stroopinsky D, Katz T. Anti-CD20 monoclonal antibodies: beyond B-cells. Blood Rev. 2013;27:217–223.
   PubMed Web of Science ®Google Scholar
• Gyurkocza B, Sandmaier BM. Conditioning regimens for hematopoietic cell transplantation: one size does not fit all. Blood. 2014;124:344–353.
   PubMed Web of Science ®Google Scholar
• Bacigalupo A, Ballen K, Rizzo D, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transplant. 2009;15:1628–1633.
   PubMed Web of Science ®Google Scholar
• Gross TG, Steinbuch M, DeFor T, et al. B cell lymphoproliferative disorders following hematopoietic stem cell transplantation: risk factors, treatment and outcome. Bone Marrow Transplant. 1999;23:251–258.
   PubMed Web of Science ®Google Scholar
• Crocchiolo R, Castagna L, El-Cheikh J, et al. Prior rituximab administration is associated with reduced rate of acute GVHD after in vivo T-cell depleted transplantation in lymphoma patients. Exp Hematol. 2011;39:892–896.
   PubMed Web of Science ®Google Scholar
• Cutler C, Kim HT, Bindra B, et al. Rituximab prophylaxis prevents corticosteroid-requiring chronic GVHD after allogeneic peripheral blood stem cell transplantation: results of a phase 2 trial. Blood. 2013;122:1510–1517.
   PubMed Web of Science ®Google Scholar
• Styczynski J, Tridello G, Gil L, et al. Impact of donor Epstein–Barr virus serostatus on the incidence of graft-versus-host disease in patients with acute leukemia after hematopoietic stem-cell transplantation: a study from the acute leukemia and infectious diseases working parties of the European Society for blood and marrow transplantation. JCO. 2016;34:2212–2220.
   PubMed Web of Science ®Google Scholar
• Auger S, Orsini M, Ceballos P, et al. Controlled Epstein–Barr virus reactivation after allogeneic transplantation is associated with improved survival. Eur J Haematol. 2014;92:421–428.
   PubMed Web of Science ®Google Scholar
• Carpenter B, Haque T, Dimopoulou M, et al. Incidence and dynamics of Epstein–Barr virus reactivation after alemtuzumab-based conditioning for allogeneic hematopoietic stem-cell transplantation. Transplantation. 2010;90:564–570.
   PubMed Web of Science ®Google Scholar
• Zallio F, Primon V, Tamiazzo S, et al. Epstein–Barr virus reactivation in allogeneic stem cell transplantation is highly related to cytomegalovirus reactivation. Clin Transplant. 2013;27:E491–E497.
   PubMed Web of Science ®Google Scholar
• Gartner B, Preiksaitis JK. EBV viral load detection in clinical virology. J Clin Virol. 2010;48:82–90.
   PubMed Web of Science ®Google Scholar
• van Esser JW, van der Holt B, Meijer E, et al. Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT. Blood. 2001;98:972–978.
   PubMed Web of Science ®Google Scholar
• Kinch A, Oberg G, Arvidson J, et al. Post-transplant lymphoproliferative disease and other Epstein–Barr virus diseases in allogeneic haematopoietic stem cell transplantation after introduction of monitoring of viral load by polymerase chain reaction. Scand J Infect Dis. 2007;39:235–244.
   PubMed Web of Science ®Google Scholar
• Worth A, Conyers R, Cohen J, et al. Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein–Barr virus-associated lymphoproliferative disease following stem cell transplantation. Br J Haematology. 2011;155:377–385.
   PubMed Web of Science ®Google Scholar
• Ahmad I, Cau NV, Kwan J, et al. Preemptive management of Epstein–Barr virus reactivation after hematopoietic stem-cell transplantation. Transplantation. 2009;87:1240–1245.
   PubMed Web of Science ®Google Scholar
• Kullberg-Lindh C, Olofsson S, Brune M, et al. Comparison of serum and whole blood levels of cytomegalovirus and Epstein–Barr virus DNA. Transpl Infect Dis. 2008;10:308–315.
   PubMed Web of Science ®Google Scholar
• Fox CP, Burns D, Parker AN, et al. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant. 2014;49:280–286.
   PubMed Web of Science ®Google Scholar
• Hale G, Waldmann H. Risks of developing Epstein–Barr virus-related lymphoproliferative disorders after T-cell-depleted marrow transplants. CAMPATH Users [Research Support, Non-U.S. Govt]. Blood. 1998;91:3079–3083.
   PubMed Web of Science ®Google Scholar